



American Society of Hematology

Helping hematologists conquer blood diseases worldwide

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial

Gang An, MD, PhD¹; Daobin Zhou, MD, PhD²; Shu Cheng, MD, PhD³; Keshu Zhou, MD, PhD⁴; Jianyong Li, MD, PhD⁵; Jianfeng Zhou, MD, PhD⁶; Liping Xie, MD, PhD⁷; Jie Jin, MD, PhD⁸; Liye Zhong, MD, PhD⁹; Lingzhi Yan, MD, PhD¹⁰; Haiyi Guo, MD¹¹; Chenmu Du, MD¹¹; Jane Huang, MD¹¹; William Novotny, MD¹¹; Jinhua Zhong, PhD¹¹; Lugui Qiu, MD¹

¹Department of Lymphoma, Chinese Academy of Medical Sciences, Blood Diseases Hospital (Institute of Hematology), Tianjin, China

²Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

³Department of Hematology, Shanghai Ruijin Hospital, Shanghai, China

⁴Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

⁵Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

⁶Department of Hematology, Tongji Hospital, Tongji Medical College, Wuhan, China

⁷Department of Hematology, West China Hospital of Sichuan University, Chengdu, China

⁸Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China

⁹Department of Hematology, Guangdong Provincial People's Hospital, Guangzhou, China

¹⁰Department of Hematology, The First Affiliated Hospital of Soochow University, Soochow, China

¹¹BeiGene (Beijing) Co., Ltd, Beijing, China; BeiGene (Shanghai) Co., Ltd, Shanghai, China; BeiGene USA, Inc., San Mateo, CA, USA

Introduction

- BTK plays a critical role in B-cell receptor signaling; this pathway is constitutively activated in WM (>90% with *MYD88* mutations), leading to malignant cell survival^{1,2}
- BTK inhibition is an emerging standard of care for WM³
- Zanubrutinib is a next-generation BTK inhibitor designed to maximize BTK occupancy and minimize off-target inhibition of TEC- and EGFR-family kinases
 - Potent, selective, irreversible
 - Equipotent to ibrutinib against BTK; higher selectivity vs EGFR, ITK, JAK3, HER2, and TEC⁴
 - Advantageous PK and PD properties: complete and sustained BTK occupancy in PBMC and lymph nodes⁵
 - Favorable drug–drug interaction properties: can be co-administered with strong/moderate CYP3A inhibitors at a reduced dose, proton pump inhibitors, acid-reducing agents, and antithrombotic agents^{6,7}
 - **Approved for patients with R/R MCL in the United States, November 2019**
 - **Approved for patients with R/R MCL and R/R CLL/SLL in China, June 2020**



BTK, Bruton tyrosine kinase; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; ITK, interleukin-2-inducible T-cell kinase; JAK3, Janus tyrosine kinase 3; MCL, mantle cell lymphoma; *MYD88*, myeloid differentiation primary response gene 88; PBMC, peripheral blood mononuclear cell; PD, pharmacodynamic; PK, pharmacokinetic; R/R, relapsed/refractory; WM, Waldenström macroglobulinemia.

1. Rickert RC. *Nat Rev Immunol.* 2013;13:578-591. 2. Argyropoulos KV, et al. *Leukemia.* 2016;30:1116-1125. 3. Treon SP et al, *J Clin Oncol.* 2020;38:1198-1208. 4. Guo Y, et al. *J Med Chem.* 2019;62:7923-7940. 5. Tam CS, et al. *Blood.* 2019;134:851-859. 6. Mu S, et al. *Cancer Chemother Pharmacol.* 2020;85:391-399. 7. Data on file.

Zanubrutinib: A Potent and Selective BTK Inhibitor^{1,2}

- Potent, selective, irreversible; minimize off-target inhibition

Targets	Assays	Zanubrutinib IC ₅₀ (nM)	Ibrutinib IC ₅₀ (nM)	Ratio (Zanubrutinib:Ibrutinib)
BTK	BTK-pY223 Cellular Assay	1.8	3.5	0.5
	Rec-1 Proliferation	0.36	0.34	1.1
	BTK Occupation Cellular Assay	2.2	2.3	1.0
	BTK Biochemical Assay	0.22	0.2	1.1
EGFR	p-EGFR HTRF Cellular Assay	606	101	6
	A431 Proliferation	3210	323	9.9
ITK	ITK Occupancy Cellular Assay	606	189	17
	p-PLC _{γ1} Cellular Assay	3433	77	45
	IL-2 Production Cellular Assay	2536	260	9.8
	ITK Biochemical Assay	30	0.9	33
JAK3	JAK3 Biochemical Assay	200	3.9	51
HER2	HER2 Biochemical Assay	661	9.4	70
TEC	TEC Biochemical Assay	1.9	0.8	2.4




bid, twice daily; BTK, Bruton tyrosine kinase; CLL, chronic lymphocytic leukemia; C_{max}, maximum concentration; C_{trough}, trough concentration; DLBCL, diffuse large B-cell lymphoma; EGFR, epidermal growth factor receptor; FL, follicular lymphoma; HER2, human epidermal growth factor receptor 2; HTRF, homogeneous time-resolved fluorescence; IC₅₀, half maximal inhibitory concentration; ITK, interleukin-2-inducible T-cell kinase; JAK3, Janus tyrosine kinase 3; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; PLC, phospholipase C; qd, once daily; WM, Waldenström macroglobulinemia; Zanu, zanubrutinib.

1. Guo Y, et al. J Med Chem. 2019;62:7923-7940. 2. Tam CS, et al. Blood. 2019;134:851-859.

Study Design

- BGB-3111-210 (ClinicalTrials.gov: NCT03332173) is a pivotal, single-arm, open-label, multicenter, phase 2 study conducted in R/R WM patients in China



Primary endpoint:

- MRR (CR + VGPR + PR rate) assessed by IRC according to an adaptation of the response criteria updated at the 6th IWWM^{1,2}

Secondary endpoints:

- PFS, ORR, DOMR, safety


Eligible patients:

- Meet at least one criterion for treatment according to consensus panel criteria from the 7th IWWM³
- WM pathology confirmation by central lab
- Previously treated with a minimum of one prior line of standard chemotherapy-containing regimen (with completion of ≥ 2 continuous treatment cycles)
- Documented failure to achieve at least minor response or documented disease progression after response to the most recent treatment regimen

bid, twice daily; CR, complete response; DOMR, duration of major response; IRC, independent review committee; IWWM, International Workshop on Waldenström's Macroglobulinemia; MRR, major response rate; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; R/R, relapsed/refractory; VGPR, very good partial response; WM, Waldenström macroglobulinemia.

1. Owen RG, et al. Br J Haematol. 2013;160:171-176. 2. Anderson KC, et al. J Natl Compr Canc Netw. 2012;10:1211-1219. 3. Dimopoulos MA, et al. Blood. 2014;124:1404-1411.

Patient Disposition (Median Follow-up: 18.58 months)



^aOne patient discontinued study treatment and subsequently died due to 'progression of Waldenström macroglobulinemia' that was reported as an adverse event.

^bThe patient achieved MR and was discontinued per the investigator's discretion.

AE, adverse event; MR, minor response; PD, progressive disease.

Patient Demographics and Disease Characteristics

Characteristic	Total (N = 44)
Median age, years (range)	65 (41–83)
Sex, n (%)	
Male	27 (61.4)
Female	17 (38.6)
ECOG performance status, n (%)	
0/1	41 (93.2)
2	3 (6.8)
WM prognostic score, n (%)	
Low risk	11 (25.0)
Intermediate risk	13 (29.5)
High risk	20 (45.5)
Median number of prior systemic therapy, regimens (range)	2 (1–6)
Median baseline IgM, g/L (range)	30.85 (3.16–96.50)
Genotype, n (%)	
<i>MYD88</i> ^{L265P} / <i>CXCR4</i> ^{WT}	32 (72.7)
<i>MYD88</i> ^{L265P} / <i>CXCR4</i> ^{WHIM}	5 (11.4)
<i>MYD88</i> ^{WT}	7 (15.9)
Peripheral blood cytopenias, n (%)	
Anemia (hemoglobin ≤ 110 g/L)	33 (75.0)
Thrombocytopenia (platelet count $\leq 100 \times 10^9$ /L)	9 (20.5)
Neutropenia (ANC $\leq 1.5 \times 10^9$ /L)	11 (25.0)

ANC, absolute neutrophil count; *CXCR4*, CXC-chemokine receptor 4; ECOG, Eastern Cooperative Oncology Group; IgM, immunoglobulin M; *MYD88*, myeloid differentiation primary response gene 88; WHIM, warts, hypogammaglobulinemia, immunodeficiency, and Myelokathexis syndrome; WM, Waldenström macroglobulinemia; WT, wild type.

Efficacy: Best Overall Response as Assessed by IRC

Efficacy per IRC	N = 43 ^a
BOR, n (%)	
CR	0
VGPR	14 (32.6)
PR	16 (37.2)
MR	4 (9.3)
SD	4 (9.3)
PD	2 (4.7)
Unknown	3 (7.0)
CR + VGPR rate, n (%); (95% CI) ^b	14 (32.6); (19.08, 48.54)
Major response rate (PR or better), n (%); (95% CI) ^b	30 (69.8); (53.87, 82.82)
Overall response rate (MR or better), n (%); (95% CI) ^b	34 (79.1); (63.96, 89.96)

^aOne patient was excluded from the efficacy analysis due to baseline immunoglobulin M <5g/L.


^bCalculated using the Clopper-Pearson method.

BOR, best overall response; CI, confidence interval; CR, complete response; IRC, independent review committee; MR, minor response; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.

Efficacy: PFS and DOMR as Assessed by IRC

- The median PFS and DOMR were not reached


Kaplan–Meier Plot of Progression-Free Survival by IRC



No. at Risk 43 41 41 36 34 34 33 32 31 30 29 28 27 27 26 25 25 10 10 10 1 1 1 0

Event-free Rate at, % (95% CI) ^a	
6 months, % (95% CI)	89.8 (75.1, 96.1)
9 months, % (95% CI)	87.0 (71.5, 94.4)
12 months, % (95% CI)	78.3 (61.2, 88.6)

Kaplan–Meier Plot of Duration of Major Response by IRC



No. at Risk 30 29 29 27 26 25 24 24 23 22 22 22 19 17 9 8 8 1 1 1 0

Event-free Rate at, % (95% CI) ^a	
6 months, % (95% CI)	96.2 (75.7, 99.4)
9 months, % (95% CI)	88.1 (67.6, 96.0)
12 months, % (95% CI)	88.1 (67.6, 96.0)

^aEstimated by Kaplan–Meier method with 95% CIs estimated using the Greenwood formula.
CI, confidence interval; DOMR, duration of major response; IRC, independent review committee; PFS, progression-free survival.

Efficacy: Time to Response as Assessed by IRC

- The response was achieved quickly. The median time to overall response was 2.76 months


Time to Response per IRC	Zanubrutinib (N = 43)
Time to VGPR or CR, months	
n	14
Median	2.87
Min, max	2.7, 11.1
Time to major response, months	
n	30
Median	2.79
Min, max	2.7, 13.8
Time to overall response, months	
n	34
Median	2.76
Min, max	0.8, 5.5

CR, complete response; IRC, independent review committee; VGPR, very good partial response.

Efficacy: IRC assessed MRR by subgroup

- Subgroup analysis revealed that the treatment benefit of zanubrutinib was generally consistent across the subgroups with adequate sample size.

Forest Plot of Major Response Rate by IRC



MRR, major response rate; MYD88, myeloid differentiation primary response gene 88; CXCR4, CXC-chemokine receptor 4; WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis syndrome; WM, Waldenström's macroglobulinemia; WT, wildtype; IRC, independent review committee.

Summary of TEAEs Regardless of Causality


Event, n (%)	N = 44
Grade ≥3 TEAEs	32 (72.7)
Serious TEAEs	22 (50.0)
TEAEs leading to study drug discontinuation	5 (11.4)
TEAEs leading to death (preferred term) ^a	2 (4.5)
Death	1 (2.3)
Multiple organ dysfunction syndrome	1 (2.3)
Acute hepatitis B	1 (2.3)
TEAEs of special interest (pooled terms)	
Hypertension	5 (11.4)
Major hemorrhage ^b	2 (4.5)
Atrial fibrillation/flutter	0
Secondary primary malignancy	3 (6.8)
Tumor lysis syndrome	0
Infection	35 (79.5)
Cytopenia	
Anemia	7 (15.9)
Neutropenia	25 (56.8)
Thrombocytopenia	13 (29.5)

^aDeath within 30 days of last dose of zanubrutinib.

^bUpper gastrointestinal hemorrhage (one subject), ecchymosis, and retinal hemorrhage (one subject).

TEAEs, treatment-emergent adverse events. A treatment-emergent AE was defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days after the last dose of study drug or initiation of new anticancer therapy, whichever occurred first.

TEAEs in $\geq 10\%$ of Patients



TEAEs, treatment-emergent adverse events. A treatment-emergent AE was defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days after the last dose of study drug or initiation of new anticancer therapy, whichever occurred first.

Note: AEs were coded using MedDRA Version 22.0. Preferred terms are listed.

Conclusions

- After a median follow-up of 18.58 months, zanubrutinib demonstrated a high, deep, quick, and durable efficacy in R/R WM patients
 - MRR was 69.8% and CR + VGPR rate was 32.6% per IRC
 - The median PFS and DOMR were not reached
 - The median time to overall response was 2.76 months
- The safety and tolerability profiles of zanubrutinib shown in this study were consistent with previous reports in WM patients
- Data from study BGB-3111-210 has been submitted to the NMPA seeking approval for zanubrutinib in WM

CR, complete response; DOMR, duration of major response; IRC, independent review committee; MRR, major response rate; NMPA, National Medical Products Administration; PFS, progression-free survival; R/R, relapsed/refractory; VGPR, very good partial response; WM, Waldenström macroglobulinemia.



Conflict of interest disclosures

There are no relationships to disclose.

Acknowledgments

- We thank the investigators, site support staff, and especially the patients for participating in this study
- This study was sponsored by BeiGene. Editorial support was provided by Twist Medical LLC and funded by BeiGene

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASH[®] and the author of this poster



Correspondence

Gang An

State Key Laboratory of Experimental Hematology,
Institute of Hematology and Blood Disease Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College,
288 Nanjing Road, Tianjin
300020, China
Email: angang@ihcams.ac.cn

